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Gordon syndrome (GS), or distal arthrogryposis type 3, is a rare, autosomal-dominant disorder characterized by cleft palate and congen-
ital contractures of the hands and feet. Exome sequencing of five GS-affected families identified mutations in piezo-type mechanosen-
sitive ion channel component 2 (PIEZO2) in each family. Sanger sequencing revealed PIEZO2 mutations in five of seven additional
families studied (for a total of 10/12 [83%] individuals), and nine families had an identical c.8057G>A (p.Arg2686His) mutation. The
phenotype of GS overlaps with distal arthrogryposis type 5 (DA5) and Marden-Walker syndrome (MWS). Using molecular inversion
probes for targeted sequencing to screen PIEZO2, we found mutations in 24/29 (82%) DA5-affected families and one of two MWS-
affected families. The presence of cleft palate was significantly associated with c.8057G>A (Fisher’s exact test, adjusted p value <
0.0001). Collectively, although GS, DA5, and MWS have traditionally been considered separate disorders, our findings indicate that
they are etiologically related and perhaps represent variable expressivity of the same condition.Gordon syndrome (GS [MIM 114300]) is a rare autosomal-
dominant disorder characterized by cleft palate and multi-
ple congenital contractures of the hands and feet.1–7
Gordon et al.1 originally described a three-generation
family with autosomal-dominant inheritance of campto-
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reported, although only a small percentage of affected in-
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Figure 1. Phenotypic Characteristics of Each GS Individual Used for Exome Sequencing and the MWS Individual with a Mutation in
PIEZO2
(A–F) Faces of individuals affected by GS. All individuals shown had PIEZO2mutations. Note the deep-set eyes and micrognathia. Each
individual had either cleft palate or a bifid uvula.
(H and I) The hands (H) and feet (I) of an individual with GS demonstrate curved fingers with straight thumbs and clubfeet, respectively.
(G) The face of an individual with MWS and a mutation in PIEZO2.
Case identifiers for the individuals shown in this figure are A:I-2 (A), A:II-1 (B), B:II-1 (C), C:II-1 (D, H, and I), D:II-1 (E), E:II-1 (F), and
II:II-1 (G) and correspond to those in Table 1, which includes a detailed description of the phenotype of each affected individual.
Figure S1 provides a pedigree of each GS-affected family, and Figure S3 provides a pedigree of the MWS-affected family (II).248700]),12–14 distal arthrogryposis type 5 (DA5 [MIM
108145]),13,14 and Schwartz-Jampel (MIM 255800).13
Furthermore, in the absence of cleft palate, GS can be virtu-
ally indistinguishable from distal arthrogryposis type 1
(DA1 [MIM 108120]) and distal arthrogryposis type 2B
(DA2B [MIM 601680]). Accordingly, Bamshad et al. catego-
rized GS as distal arthrogryposis type 3 (DA3) in the revised
classification of distal arthrogryposis (DA) syndromes but
questioned whether GS was an etiologically distinct syn-
drome.7
In an effort to ascertain GS cases for gene-mutation-
discovery studies, we reviewed phenotypic data from 170
families affected by DA1, DA2B, DA3, or DA5 of unknown
genetic etiology and identified 12 families affected by a
phenotype consistent with GS (Figure 1; Table 1;The AmFigure S1, available online). At least one affected individual
in each of these GS-affected families had cleft palate and
congenital contractures affecting both the hands and
feet. All studies were approved by the institutional review
boards of the University of Washington and Seattle Chil-
dren’s Hospital, and informed consent was obtained from
participants or their parents. To identify causative muta-
tions for GS, we first used Sanger sequencing to screen
the proband of each GS-affected family for mutations in
genes including TPM2 (MIM 190990), TNNT3 (MIM
600692), TNNI2 (MIM 191043), and MYH3 (MIM
160720), known to associate with DA1 or DA2B. We also
screenedCHRNG (MIM 100730), mutations in which cause
congenital contractures in Escobar syndrome (MIM
265000).21erican Journal of Human Genetics 94, 734–744, May 1, 2014 735
Table 1. Mutations and Clinical Findings of Individuals with GS, DA5, or MWS
Family Subject
Mutation Information (PIEZO2) Clinical Findings
Exon cDNA Change
Predicted
Protein
Alteration CP or BU
Short
Stature Micrognathia Ptosis Ophthalmoplegia Scoliosis
Pulmonary
Disease
Cognitive
Delay
Cerebellar
Malformations
GS
A I-211 52 c.8057G>A p.Arg2686His BU þ    þ   
II-111 52 c.8057G>A p.Arg2686His CP þ þ      
II-211 52 c.8057G>A p.Arg2686His CP þ þ      
II-3 52 c.8057G>A p.Arg2686His CP þ þ      
B II-1 52 c.8238_8245del8 p.Trp2746* CP þ þ þ  þ   
C II-1 52 c.8057G>A p.Arg2686His CP ND þ   rigid   
D II-1 52 c.8057G>A p.Arg2686His CP ND þ     
E II-1 52 c.8057G>A p.Arg2686His CP  þ  þ    ND
F II-1 52 c.8057G>A p.Arg2686His BU  þ mild     
G I-2 52 c.8057G>A p.Arg2686His BU ND þ   þ   ND
II-1 52 c.8057G>A p.Arg2686His CP ND þ þ ND   þ/ ND
H II-1 52 c.8057G>A p.Arg2686His CP þ ND   þ  þ/ Chiari I malformation
I II-1 52 c.8057G>A p.Arg2686His CP þ þ þ  þ   Chiari I malformation
J I-2 52 c.8057G>A p.Arg2686His CP þ   þ þ   Chiari I malformation
II-1 52 c.8057G>A p.Arg2686His CP þ  mild     
DA5
K I-2 52 c.8153G>T p.Arg2718Leu     þ  þ  ND
II-2 52 c.8153G>T p.Arg2718Leu     þ  þ  ND
II-3 52 c.8153G>T p.Arg2718Leu     þ    ND
II-5 52 c.8153G>T p.Arg2718Leu     þ  þ  ND
II-6 52 c.8153G>T p.Arg2718Leu         ND
III-1 52 c.8153G>T p.Arg2718Leu     þ    ND
III-4 52 c.8153G>T p.Arg2718Leu     þ    ND
III-6 52 c.8153G>T p.Arg2718Leu     þ    ND
III-7 52 c.8153G>T p.Arg2718Leu    mild þ    ND
(Continued on next page)
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Table 1. Continued
Family Subject
Mutation Information (PIEZO2) Clinical Findings
Exon cDNA Change
Predicted
Protein
Alteration CP or BU
Short
Stature Micrognathia Ptosis Ophthalmoplegia Scoliosis
Pulmonary
Disease
Cognitive
Delay
Cerebellar
Malformations
L II-515 52 c.8181_8183delAGA p.Glu2727del  þ  mild
BL
BL þ þ  ND
II-715 NT NT NT  þ   BL stiff þ  ND
III-715 52 c.8181_8183delAGA p.Glu2727del    BL BL  þ  ND
M II-416 15 c.2134A>G p.Met712Val  þ  ND     ND
III-116 15 c.2134A>G p.Met712Val  þ  mild
BL
þ þ   ND
IV-316 15 c.2134A>G p.Met712Val  þ  mild  þ þ  ND
IV-416 NA no c.2134A>G NA  þ  ND     ND
N III-3 45 c.7067C>T p.Thr2356Met   þ þ þ    
IV-3 45 c.7067C>T p.Thr2356Met    þ þ stiff   ND
IV-5 45 c.7067C>T p.Thr2356Met  ND  mild þ    ND
V-3 45 c.7067C>T p.Thr2356Met  ND  þ þ    ND
O II-5 52 c.8181_8183delAGA p.Glu2727del  þ  mild þ    ND
III-4 52 c.8181_8183delAGA p.Glu2727del     þ    ND
III-5 52 c.8181_8183delAGA p.Glu2727del    ND þ    ND
P I-117,18 52 c.8153G>T p.Arg2718Leu  þ  BL BL stiff   ND
II-117 52 c.8153G>T p.Arg2718Leu  ND  BL BL    ND
Q II-119 52 c.8215T>C p.Ser2739Pro  þ  R BL    ND
III-219 52 c.8215T>C p.Ser2739Pro    mild
BL
þ    ND
R II-1 52 c.8181_8183delAGA p.Glu2727del  þ ND mild
BL
BL ND ND  ND
III-2 52 c.8181_8183delAGA p.Glu2727del  þ ND mild
BL
BL ND ND  ND
S II-2 43 c.6662C>T p.Thr2221Ile   þ mild þ þ   ND
III-1 43 c.6662C>T p.Thr2221Ile   þ BL þ þ   ND
T II-1 52 c.8181_8183delAGA p.Glu2727del    mild þ Y ROM   ND
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Table 1. Continued
Family Subject
Mutation Information (PIEZO2) Clinical Findings
Exon cDNA Change
Predicted
Protein
Alteration CP or BU
Short
Stature Micrognathia Ptosis Ophthalmoplegia Scoliosis
Pulmonary
Disease
Cognitive
Delay
Cerebellar
Malformations
U II-2 52 c.8181_8183delAGA p.Glu2727del ND ND  mild ND ND ND  ND
III-1 52 c.8181_8183delAGA p.Glu2727del ND ND  mild ND ND ND  ND
V II-1 52 c.8181_8183delAGA p.Glu2727del  ND ND ND þ rigid ND  ND
III-1 52 c.8181_8183delAGA p.Glu2727del  ND ND ND þ rigid ND  ND
W II-2 15 c.2134A>G p.Met712Val    þ BL þ þ  
III-1 15 c.2134A>G p.Met712Val  þ  BL BL    ND
X II-220 52 c.8057G>A p.Arg2686His    BL BL stiff   
Y II-1 52 c.8057G>A p.Arg2686His    mild þ þ þ/  ND
Z III-1 52 c.8181_8183delAGA p.Glu2727del    þ þ    ND
AA III-2 52 c.8181_8183delAGA p.Glu2727del  þ  mild  stiff   ND
BB III-1 43 c.6662C>T p.Thr2221Ile    mild BL    ND
CC II-1 43 c.6668C>T p.Ser2223Leu  þ  þ þ    
DD II-1 52 c.8181_8183delAGA p.Glu2727del    þ þ    ND
EE II-2 52 c.8208delA p.Tyr2737Ilefs*7  þ  þ þ    
FF II-1 52 c.8153G>C p.Arg2718Pro    þ þ þ þ  ND
GG II-2 20 c.2993T>C p.Met998Thr  þ  BL BL þ þ  
HH II-210 52 c.8181_8183delAGA p.Glu2727del  þ  ND þ/ x þ   
III-110 52 c.8181_8183delAGA p.Glu2727del    mild
BL
þ/ x þ þ  
III-210 52 c.8181_8183delAGA p.Glu2727del  þ  mild
BL
BL þ þ/  Dandy-Walker
malformation
MWS
II II-1 52 c.8056C>T p.Arg2686Cys CP  þ þ ND þ  þ Dandy-Walker
malformation
This table provides a summary of clinical features of affected individuals from families in which PIEZO2 mutations were identified. Clinical characteristics listed in the table are primarily features that distinguish the different
diagnoses (GS, DA5, andMWS). In addition to showing the characteristics listed in the table, affected individuals had contractures of the hands and feet, which are characteristic of DA disorders. Abbreviations are as follows:þ,
presence of a finding; , absence of a finding; þ/, possible or very mild features; BL, bilateral; BU, bifid uvula; CP, cleft palate; ND, no data available; NT, not tested; ROM, range of motion; and x, described as Brown
syndrome.
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Next, we selected five GS-affected families in which the
affected individual had facial characteristics similar to
those of affected individuals from GS-affected families in
which vertical transmission of GS was evident. Each
GS proband was screened for copy-number variations
(CNVs) by array comparative genomic hybridization on
the Illumina HumanCytoSNP-12. No pathogenic muta-
tions or shared CNV regions were identified. Next, exome
sequencing was performed on four GS parent-child trios
(three simplex cases [from families B–D] and one family
with an affected mother and son [family A]) and a single
affected individual (from family E) (Figure 1; Figure S1).
In brief, 1 mg of genomic DNA was subjected to a series
of shotgun-library-construction steps, including fragmen-
tation through acoustic sonication (Covaris), end polish-
ing (NEBNext End Repair Module), A-tailing (NEBNext
dA-Tailing Module), and ligation of 8 bp barcoded
sequencing adaptors (Enzymatics Ultrapure T4 Ligase).
Prior to exome capture, the library was amplified via PCR
(BioRad iProof). One microgram of barcoded shotgun
library was hybridized for capture of probes targeting
64 Mb of coding exons (Roche Nimblegen SeqCap EZ
Human Exome Library v.2.0) according to the manufac-
turer’s protocol, and custom blockers complimentary to
the full length of the flanking adaptor and barcodes were
added. Enriched libraries were amplified via PCR before
sequencing (BioRad iProof). Library quality was deter-
mined by examination of molecular-weight distribution
and sample concentration (Agilent Bioanalyzer). Pooled,
barcoded libraries were sequenced via paired-end 50 bp
reads with an 8 bp barcode read on Illumina HiSeq
sequencers.
Demultiplexed BAM files were aligned to the human
reference genome (hg19, UCSC Genome Browser) with
the Burrows-Wheeler Aligner (BWA).22 Read data from a
flow-cell lane were treated independently for alignment
and quality-control purposes in instances where the merg-
ing of data from multiple lanes was required. All aligned
read data were subjected to (1) removal of duplicate reads
(Picard), (2) indel realignment by the Genome Analysis
Toolkit (GATK) IndelRealigner, and (3) base-quality recali-
bration by the GATK TableRecalibration. Variant detection
and genotyping were performed with the UnifiedGeno-
typer tool from GATK (v.1.529). Variant data for each
sample were formatted (variant call format) as ‘‘raw’’ calls
that contained individual genotype data for one or multi-
ple samples and were flagged with the filtration walker
(GATK) for marking sites that were of lower quality and
potential false positives (e.g., quality scores % 50, allelic
imbalance R 0.75, long homopolymer runs > 3, and/or
low quality by depth < 5). Variants were annotated with
SeattleSeq Annotation 134, and variants with an alterna-
tive allele frequency > 0.01 in the NHLBI Exome
Sequencing Project Exome Variant Server (ESP6500) or
1000 Genomes Project23 or > 0.2 in an internal database
derived from other University of Washington Center for
Mendelian Genomics exomes were excluded prior to anal-The Amysis. Additionally, intergenic variants or variants that were
flagged as low quality or potential false positives (quality
scores % 30, long homopolymer runs > 5, low quality by
depth < 5, within a cluster of SNPs) were also excluded
from analysis. Variants that were only flagged by a strand
bias (strand bias R 0.10) or allele-balance filter (allelic
imbalance R 0.75) were included in further analyses
because both flags have previously been found to be
applied to valid pathogenic variants. CNV calls were also
generated from exome data with CoNIFER.24
Analysis of variants from exome sequencing under a
model matching the predicted pattern of inheritance
(autosomal dominant in family A and de novo in families
B–E; Figure S1) identified mutations in a single gene, piezo-
type mechanosensitive ion channel component 2 (PIEZO2
[MIM 613629; RefSeq accession number NM_022068.2]),
in all five GS-affected families. Specifically, in four families
(A and C–E), a recurrent missense mutation (c.8057G>A)
predicted to cause a nonconservative arginine-to-histidine
substitution (p.Arg2686His) was found in each family. An
8 bp deletion (c.8238_8245del8) predicted to result in an
immediate stop codon (p.Trp2746*) was found to be de
novo in a single trio (family B). Neither mutation was
found in ESP6500, the 1000 Genomes Project (phase 1
release),23 or internal databases (>1,400 chromosomes).
Sanger sequencing confirmed each variant identified. In
families C–E, the c.8057G>A mutation was found to
have arisen de novo. In family A, c.8057G>A was trans-
mitted from an affected mother to her affected offspring,
and Sanger sequencing confirmed that the two other
affected individuals in family A also carried the
c.8057G>A mutation.
To determine the extent to which mutations in PIEZO2
cause GS, we used molecular inversion probes (MIP)25,26
for targeted sequencing of PIEZO2 in seven additional
GS-affected families. MIPs can be used for multiplex tar-
geted sequence capture, followed by massively parallel
sequencing of capture products. This strategy is efficient
and cost effective for sequencing large genes, such as the
52-exon gene PIEZO2, in modest to large sample sets.
Pooled and phosphorylated MIP probes targeting
8,259 bp of PIEZO2 coding sequence plus 20 bp of
intron-exon flanking regions were designed10 and used
in capture reactions with 100 ng of genomic DNA from
each individual. PCR was performed with universal
primers, and unique 8-base sample indexes were intro-
duced on the tagged reverse primer. The individual
samples were then pooled, and the resulting library was
purified with magnetic beads (Agencourt AMPure XP).
After Picogreen quantification for determining the appro-
priate dilution, the library was sequenced on an Illumina
MiSeq system. The alignment (BWA v.0.5.9-r16), analysis
(GenomeAnalysisTK-2.3-4-g57ea19f.), and filtering (Seat-
tleSeq Annotation 137) of the variants were similar to
the filtering of exome variants in that candidate nonsy-
nonymous, nonsense, and deletion and/or duplication
coding variants or splicing variants that were not seen inerican Journal of Human Genetics 94, 734–744, May 1, 2014 739
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Figure 2. Genomic Structure and Spectrum of PIEZO2 Mutations that Cause GS, DA5, or MWS
PIEZO2 is composed of 52 exons that encode protein-coding sequence (blue). Arrows indicate the locations of 13 different mutations
found in 35 families affected by GS, DA5 or MWS. The U symbol indicates mutations that were inherited in families with an auto-
somal-dominant pattern of inheritance, and the y symbol indicates mutations that were confirmed to be de novo in simplex cases.
PIEZO2 mutations identified in GS, DA5, and MWS individuals are indicated by red, yellow, and green circles, respectively.variant databases were chosen for further confirmation by
Sanger sequencing. MIP sequencing of PIEZO2 and variant
confirmation in probands and family members by Sanger
sequencing identified the same missense mutation
(c.8057G>A [p.Arg2686His]) in PIEZO2 in five additional
families affected by GS. Altogether, mutations in PIEZO2
were found in 10 of 12 GS-affected families, and nine of
ten families shared the same missense mutation. All ten
mutations occurred in exon 52 (Figure 2).
Mutations in PIEZO2 have recently been reported to
cause congenital contractures and ophthalmoplegia in
two families affected by DA5.27 Accordingly, the observa-
tion that the phenotypic characteristics of GS and
DA5 overlap is consistent with the discovery that muta-
tions in PIEZO2 also cause GS. Indeed, among the 15 GS-
affected individuals (from ten families) in whom we found
PIEZO2 mutations, five also had ptosis and two had
ophthalmoplegia.
To further explore the genetic and phenotypic overlap
with DA5, we used a combination of MIP and Sanger
sequencing to screen PIEZO2 in 29 families affected
by DA5. Mutations in PIEZO2 were found in 24/29 (83%)
DA5-affected families (Tables 1 and 2; Figure 2; Figures S2
and S5), including 14/16 (88%) familial cases and 10/13
(77%) simplex cases. Forty-two percent (10/24) of
DA5-affected families had the same recurrent
c.8181_8183delAGA (p.Glu2727del) mutation (Table 2).
In one DA5-affected family (family Z, Figure S2), the
c.8181_8183delAGA mutation found in the proband was
also detected at a low level (11%) in a DNA sample
obtained from peripheral blood in his unaffected father
(Figure S4). The presence of this mutation was confirmed
in DNA sampled from both buccal cells (10%) and
saliva (12%). This observation suggests that either the
penetrance of c.8181_8183delAGA was incomplete and/
or the level of mosaicism in the father was too low to cause
the phenotypic characteristics of DA5. Two simplex cases
of DA5 (in families X and Y, Figure S2) had a recurrent
c.8057G>A (p.Arg2686His) mutation, the same one740 The American Journal of Human Genetics 94, 734–744, May 1, 2found to cause GS (Table 2). Neither individual had a cleft
palate.
GS and DA5 are phenotypically similar to MWS, a rare
disorder for which the genetic basis has not yet been
discovered. MWS has been hypothesized to be etiologically
related to both DA12,28 and GS.14 Therefore, we hypothe-
sized that mutations in PIEZO2 might also cause MWS.
MWS is characterized by joint contractures including
camptodactyly, cleft palate, blepharophimosis, ‘‘immobile
facies,’’ diminished muscular bulk, developmental delay,
and hindbrain malformations, most commonly Dandy-
Walker malformation. The latter is notable because hind-
brain malformations were found in several individuals
with PIEZO2mutations and either GS or DA5. Specifically,
three of the families affected by GS had a Chiari I malfor-
mation, and one individual with DA5 had a Dandy-Walker
malformation. Sequencing of PIEZO2 in two cases of MWS
revealed a de novo c.8056C>T (p.Arg2686Cys) mutation
in one family. Whereas this mutation is predicted to cause
a cysteine substitution in MWS, mutation of the adjacent
nucleotide (c.8057G>A) is predicted to cause a histidine
substitution for the same arginine in amino acid position
2686 (p.Arg2686His) in GS and DA5 (Table 2).
Collectively, we identified 13 different mutations in
PIEZO2 (Figure 2; Table 2) in 35 families affected by GS
(n ¼ 10), DA5 (n ¼ 24), or MWS (n ¼ 1). Ten of these
mutations are missense, two are predicted to cause a frame-
shift, and one is a 3 bp in-frame deletion (Table 2). Recur-
rent mutations occurred at five sites, and two of these
(c.8057G>A [p.Arg2686His] and c.8181_8183delAGA
[p.Glu2727del]) were observed in ten or more families
and arose de novo (six missense and three deletions) in
nine of these families. Although the sample size is small,
these sites could represent mutation hotspots in PIEZO2.
The phenotypes of GS, DA5, and MWS are distinguished
from one another by just a few major characteristics.
However, some individuals with mutations in PIEZO2
had characteristics that spanned more than one of these
diagnoses (Figure 3). Furthermore, the c.8057G>A014
Table 2. Summary of PIEZO2 Mutations Found in Individuals with GS, DA5, or MWS
Exon
Mutation Information Number of Families Inheritance
cDNA Change GERP Protein Alteration Type Total GS DA5 MWS De Novo AD
15 c.2134A>G 4.80 p.Met712Val missense 2 0 2 0 þ þ
20 c.2993T>C 4.99 p.Met998Thr missense 1 0 1 0 þ 
43 c.6662C>T 4.68 p.Thr2221Ile missense 2 0 2 0 þ þ
43 c.6668C>T 5.55 p.Ser2223Leu missense 1 0 1 0 þ 
45 c.7067C>T 4.64 p.Thr2356Met missense 1 0 1 0  þ
52 c.8057G>A 4.62 p.Arg2686His missense 11 9 2 0 þ þ
52 c.8056C>T 4.62 p.Arg2686Cys missense 1 0 0 1 þ 
52 c.8153G>T 5.24 p.Arg2718Leu missense 2 0 2 0  þ
52 c.8153G>C 5.24 p.Arg2718Pro missense 1 0 1 0 þ 
52 c.8181_8183delAGA NA p.Glu2727del in-frame deletion 10 0 10 0 þ þ
52 c.8208delA NA p.Tyr2737Ilefs*7 single bp deletion 1 0 1 0 þ 
52 c.8215T>C 4.71 p.Ser2739Pro missense 1 0 1 0  þ
52 c.8238_8245 del8 NA p.Trp2746* 8 bp deletion 1 1 0 0 þ 
Total 35 10 24 1
This table summarizes the mutations identified in 35 families affected by GS (n ¼ 10), DA5 (n ¼ 24), or MWS (n ¼ 1). GERP scores provide an estimate of con-
servation across species at a nucleotide site; a more positive score is associated with deleteriousness. Abbreviations are as follows: AD, autosomal dominant, GERP,
Genomic Evolutionary Rate Profiling; and NA, not applicable.(p.Arg2686His) mutation, which explains most of the GS
cases, was found in two DA5-affected families (i.e., families
X and Y). This observation raises the question as to
whether GS, DA5, and MWS are distinct syndromes or
different manifestations of the same condition.
One explanation for the overlap of clinical phenotypes
among these syndromes is that there is a strong geno-
type-phenotype relationship between PIEZO2 mutations
and the major characteristics that vary among GS, DA5,
andMWS. Accordingly, we tested whether c.8181_8183de-
lAGA and c.8057G>A were associated with the presence of
cleft palate, pulmonary disease, ophthalmoplegia, scoli-
osis, or cerebellar malformation regardless of diagnosis.
Cleft palate was significantly associated (Fisher’s exact
test, adjusted p value < 0.0001) with c.8057G>A, but no
other associations were significant. All of the individuals
with GS and a c.8057G>A mutation had either cleft palate
(n ¼ 12) or a bifid uvula (n ¼ 2), but only four were
reported to have ptosis and only one had ophthalmople-
gia. These findings suggest that the phenotype caused by
c.8057G>A is a distinct entity, namely GS. Yet, neither of
the individuals with the c.8057G>A mutation in the two
DA5-affected families had cleft palate or a bifid uvula.
Given the reduced penetrance of cleft palate in GS, we
suspect that the correct diagnosis in these two families is
GS rather than DA5.
Eighty-five percent (11/13) of the mutations we identi-
fied in PIEZO2 are predicted to alter amino acids in
the intracellular C-terminal domain of PIEZO2. The
C-terminal domain is highly conserved across metazoans,The Amalthough its function is unknown. Nevertheless, its integ-
rity appears to be vital to the function of PIEZO2 in normal
physiology and development of skeletal muscle. Moreover,
at least two PIEZO2 regions that encode the C-terminal
domain (c.8057G and c.8181_8183delAGA) appear to be
hotspots for mutations, more intolerant of variation, or
some combination thereof.
PIEZO2 and PIEZO1 are large, transmembrane protein
components of mechanically or stretch-activated ion
channels found in many tissues.29 Recent electrophysio-
logical studies of two individuals with DA5 have revealed
that c.8181_8183delAGA (p.Glu2727 del) is a gain-of-
function mutation that causes PIEZO2-dependent, me-
chanically activated currents to inactivate slower but
recover faster from this inactivation. As a result, altered
channels transduce repetitive mechanical signals more
efficiently.27 One of the more unusual clinical characteris-
tics of individuals with DA5 is that their muscles, particu-
larly the muscles of the anterior chest wall, feel firm or
‘‘woody’’ on palpation, suggesting that resting muscle
tone might be higher. Additionally, some individuals
with DA5 develop progressive pulmonary insufficiency
partly because of restrictive chest disease. Furthermore, in
contrast to other DA disorders, the contractures of some in-
dividuals with DA5 appear to worsen with age despite
intervention (e.g., physical therapy). Collectively, these
observations suggest that in addition to affecting the
development of skeletal muscle, dysregulated mechano-
transduction due to PIEZO2 mutations might also affect
the function of skeletal muscles after birth.erican Journal of Human Genetics 94, 734–744, May 1, 2014 741
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Figure 3. Phenotype Overlap among
Families Affected by PIEZO2 Mutations
and GS, DA5, or MWS
Individuals with GS, DA5, or MWS share
common clinical findings, including short
stature, curved fingers with straight
thumbs, and foot contractures and/or an
increased space between the first and sec-
ond toes (the so-called ‘‘sandal gap’’). Spe-
cific additional clinical features (e.g., cleft
palate in GS, ophthalmoplegia in DA5,
and cerebellar malformations in MWS) are
typically used for distinguishing these con-
ditions from one another. Representative
facial photos of individuals with GS
(C:II-1), DA5 (Y:II-1), and MWS (II:II-1)
are shown. In families affected by PIEZO2
mutations, some individuals had ‘‘interme-
diate phenotypes,’’ that is, they shared so-
called ‘‘distinguishing features’’ among
GS, DA5, and MWS. Individual E:II-1 had
both cleft palate and ophthalmoplegia, in-
dividual I:II-1 had both cleft palate and a
cerebellar malformation, and individual
J:I-2 had cleft palate, ophthalmoplegia,
and a cerebellar malformation.The absence of a PIEZO2mutation in two GS individuals
and one MWS individual suggests that both could be
genetically heterogeneous. However, it is likely that that
our sequencing strategy using MIPs could not reliably
detect some indels, including single-exon deletions. To
assess whether deletions or duplications that include
PIEZO2 might indeed be responsible for some cases of GS
or MWS, we queried the DECIPHER database and identi-
fied 44 individuals with either deletions (n ¼ 22) or dupli-
cations (n ¼ 22) over the region containing all or part of
PIEZO2. For the 30 of these individuals for whom pheno-
typic information was available, ten had a feature that
could be considered to be within the GS and DA5 pheno-
type spectrum. Specifically, seven had some type of
congenital contracture, three had cleft palate, and two
had ptosis. Only two of these ten individuals had more
than one of these characteristics. None of the individuals
with the smallest deletions that included PIEZO2 had
any of these features. This observation is consistent with
the findings of Coste et al., who reported that DA5 is
caused by gain-of-function, rather than loss-of-function,
mutations in PIEZO2.27
The hypothesis that the DA5 phenotype in individuals
with PIEZO2 mutations might reflect ion channel hyper-
responsiveness to forces engendered during development
and later during postnatal life27 could extend to GS and
MWS as well. Mechanotransduction plays an important
role during normal development of multiple-organ sys-742 The American Journal of Human Genetics 94, 734–744, May 1, 2014tems, including the CNS. In the brain,
for example, mechanical interaction
between cells and their environment
affects the speed and directionality of
neuronal migration.30 How mechani-cal forces are sensed and transduced by such cells is
unclear. PIEZO2 is expressed in the brain, including the
hindbrain, but there is virtually no information available
about its role, if any, in the development of the CNS. The
observation that some individuals with GS, DA5, or
MWS and PIEZO2 mutations have hindbrain malforma-
tions offers perhaps a window for further investigation.
In summary, we used exome sequencing to discover that
mutations in PIEZO2 cause GS and MWS. Furthermore, we
found that mutations in PIEZO2 also explain the over-
whelming majority of cases of DA5. The genetic and
phenotypic overlap among these three conditions sup-
ports a shared developmental mechanism, although the
presence of a genotype-phenotype relationship in GS sug-
gests that certain functions of PIEZO2 might be perturbed
by the disruption of specific residues or domains. Along
with our recent report that mutations in ECEL1 (MIM
605896) cause distal arthrogryposis type 5D31 (DA5D
[MIM 615065]), the present study suggests that DA5 and
its subtypes are caused by a disturbance of the neuromus-
cular pathways that influence the development of skeletal
muscle, whereas other DA types are caused bymutations in
genes that encode proteins of the contractile apparatus.
Although DA5 and its subtypes appear to be phenotypi-
cally distinct from other DAs, particularly the much
more common DA1 and DA2B,32 distinguishing DA5
from other DAs in a clinical setting is often challenging.
Accordingly, the existing heuristic classification of DAs
appears to be a helpful tool for prioritizing the differential
diagnosis. Yet, because natural history varies widely among
different DA disorders, including between DA5D and DA5,
identification of the underlying causal variant is essential.Supplemental Data
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